Annovis Bio Inc

ANVSNYSE · USD
1.14USD0.00 (+3.64%)
162

Annovis Bio Inc (ANVS) Covered Calls

As of September 18, 2026, ANVS has 3 covered call opportunities in the coming three months. Return ranges from 95.5 to 590.9% until expiration. Annualized return ranges from 105.5 to 473.0%. The nearest expiration is April 16, 2027. Maximum potential profit is $650.

Read more

Running ANVS covered calls helps you generate consistent income from Annovis Bio Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Annovis Bio Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ANVS covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ANVS stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANVS covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Annovis Bio Inc covered call is worth writing.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.

The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Income-focused investors, long-term ANVS holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ANVS covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Annovis Bio Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile67.06% Elevated
  • Market cap (M$)49
  • 52 weeks high-79.27%
  • 52 weeks low9.62%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$10.50
    821.05% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-11
  • P/E
  • Future P/E
  • EPS (ttm)-1.79
  • EPS growth next 5 years-2.67%

As of September 18, 2026

2027-12-174567.50581.820.100.90650.00590.91472.99-9.09+0.622,1450.80
2027-04-162112.0081.820.150.85105.0095.45165.12-13.64+0.67410.70
2027-12-174562.50127.270.050.95145.00131.82105.51-4.55+0.661,3460.90

As of September 18, 2026

Sell covered calls with the data behind you

Find the best ANVS covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial